Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03498716




Registration number
NCT03498716
Ethics application status
Date submitted
28/02/2018
Date registered
17/04/2018
Date last updated
21/08/2024

Titles & IDs
Public title
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Scientific title
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer
Secondary ID [1] 0 0
2016-003695-47
Secondary ID [2] 0 0
WO39391
Universal Trial Number (UTN)
Trial acronym
IMpassion030
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Triple Negative Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Dose-dense Doxorubicin or dose-dense Epirubicin
Treatment: Drugs - Cyclophosphamide

Experimental: Atezolizumab + Chemotherapy - Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose

Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

Active comparator: Chemotherapy - Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)


Treatment: Drugs: Atezolizumab
Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.

Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year

Treatment: Drugs: Paclitaxel
Paclitaxel will be administered by IV, 80 mg/m\^2 every week for 12 weeks.

Treatment: Drugs: Dose-dense Doxorubicin or dose-dense Epirubicin
Dose-dense doxorubicin will be administered by IV, 60 mg/m\^2 every 2 weeks for a total of 4 doses.

Or

Dose-dense epirubicin will be administered by IV, (90 mg/m\^2) every 2 weeks for a total of 4 doses

Treatment: Drugs: Cyclophosphamide
Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Invasive Disease-Free Survival (iDFS)
Timepoint [1] 0 0
From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)
Secondary outcome [1] 0 0
Invasive Disease-Free Survival (iDFS) in the Subpopulation With Programmed Death-ligand 1 (PD-L1) Selected Tumor Status (IC1/2/3)
Timepoint [1] 0 0
From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)
Secondary outcome [2] 0 0
Invasive Disease-Free Survival (iDFS) in the Node Positive Subpopulation
Timepoint [2] 0 0
From randomization until the occurrence of an iDFS event or death from any cause, whichever occurred earlier (up to 5 years)
Secondary outcome [3] 0 0
Overall Survival (OS)
Timepoint [3] 0 0
From randomization up to death from any cause (up to 5 years)
Secondary outcome [4] 0 0
Invasive Disease-Free Survival (iDFS) Including Second Primary Non-Breast Invasive Cancer
Timepoint [4] 0 0
From randomization up to death from any cause (up to 5 years)
Secondary outcome [5] 0 0
Recurrence-Free Interval (RFI)
Timepoint [5] 0 0
From randomization up to 5 years
Secondary outcome [6] 0 0
Distant Recurrence-Free Interval (DRFI)
Timepoint [6] 0 0
From randomization up to 5 years
Secondary outcome [7] 0 0
Disease-Free Survival (DFS)
Timepoint [7] 0 0
From randomization up to first disease recurrence or death from any cause (up to 5 years)
Secondary outcome [8] 0 0
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) Patient-reported Function (Role Functioning [Q6, Q7])
Timepoint [8] 0 0
Baseline (Cycle 1 Day 1), Day 1 of Cycles 4, 6, 8, 10, 12, 14 & 16; end of treatment/discontinuation (approximately at Day 351); Follow up: Months 3 to 48 (Total duration is up to 5 years); Cycles 1-5= 28 day cycles; Cycles 6-16: 21 day cycles
Secondary outcome [9] 0 0
Change From Baseline in EORTC QLQ-C30 Patient-reported Function (Physical Functioning [Q1-Q5])
Timepoint [9] 0 0
Baseline (Cycle 1 Day 1), Day 1 of Cycles 4, 6, 8, 10, 12, 14 & 16; end of treatment/discontinuation (approximately at Day 351); Follow up: Months 3 to 48 (Total duration is up to 5 years); Cycles 1-5= 28 day cycles; Cycles 6-16: 21 day cycles
Secondary outcome [10] 0 0
Change From Baseline in EORTC QLQ-C30 Global Health Status (GHS) [Q29] and Health-Related Quality of Life (HRQoL) [Q30] Combined Score
Timepoint [10] 0 0
Baseline (Cycle 1 Day 1), Day 1 of Cycles 4, 6, 8, 10, 12, 14 & 16; end of treatment/discontinuation (approximately 351 days); Follow up: Months 3 to 48 (Total duration is up to 5 years); Cycles 1-5= 28 day cycles; Cycles 6-16: 21 day cycles
Secondary outcome [11] 0 0
Number of Participants With Adverse Events (AE)
Timepoint [11] 0 0
Up to 5 years
Secondary outcome [12] 0 0
Serum Concentration of Atezolizumab
Timepoint [12] 0 0
Postdose Day 1 of Cycle 1; Predose Day 1 of Cycles 2, 3, and 4; Predose Cycles 6, 10, and 14; Predose Day 2 of Cycle 16; Cycles 1-5= 28-day cycles; Cycles 6-16: 21-day cycles
Secondary outcome [13] 0 0
Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
Timepoint [13] 0 0
Up to 5 years

Eligibility
Key inclusion criteria
* Non-metastatic operable Stage II-III breast cancer
* Histologically documented TNBC (Triple Negative Breast Cancer)
* Confirmed tumor PD-L1 evaluation as documented through central testing of a representative tumor tissue specimen
* Adequately excised: Patients must have undergone either breast-conserving surgery or mastectomy/nipple- or skin-sparing mastectomy
* Adequate hematologic and end-organ function
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm.
* No more than 8 weeks (56 days) may elapse between definitive breast surgery and randomization.
* Representative formalin-fixed, paraffin embedded (FFPE) tumor specimen from surgical resection in paraffin blocks (preferred) or at least 25 unstained slides.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Prior history of invasive breast cancer
* For the currently diagnosed breast cancer, any previous systemic anti-cancer treatment (e.g., neoadjuvant or adjuvant), including, but not limited to, chemotherapy, anti-HER2 therapy.
* Previous therapy with anthracyclines or taxanes for any malignancy
* Cardiopulmonary dysfunction
* Prior malignancies within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
* Active or history of autoimmune disease or immune deficiency
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
* Urinary outflow obstruction
* Active tuberculosis
* Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment or anticipation of need for a major surgical procedure during study treatment or within 5 months following the last dose of Atezolizumab (for patients randomized to Atezolizumab)
* Prior allogeneic stem cell or solid organ transplant
* Treatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/08/2023
Sample size
Target
Accrual to date
Final
2199
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
St Vincent's Hospital Sydney - Darlinghurst
Recruitment hospital [2] 0 0
Lismore Base Hospital - Lismore
Recruitment hospital [3] 0 0
Macquarie University Hospital - Macquarie Park
Recruitment hospital [4] 0 0
Sydney Adventist Hospital - Wahroonga
Recruitment hospital [5] 0 0
Icon Cancer Care Wesley - Auchenflower
Recruitment hospital [6] 0 0
Icon Cancer Foundation; Icon Cancer Care Chermside - Chermside
Recruitment hospital [7] 0 0
Icon Cancer Care South Brisbane - South Brisbane
Recruitment hospital [8] 0 0
Mater Hospital; Cancer Services - South Brisbane
Recruitment hospital [9] 0 0
Icon Cancer Foundation; Icon Cancer Care Southport - Southport
Recruitment hospital [10] 0 0
Princess Alexandra Hospital; Cancer Trials Unit - Woolloongabba
Recruitment hospital [11] 0 0
Royal Adelaide Hospital; Cancer Centre - Adelaide
Recruitment hospital [12] 0 0
Ashford Cancer Center Research - Kurralta Park
Recruitment hospital [13] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [14] 0 0
Austin Hospital Olivia Newton John Cancer Centre - Heidelberg
Recruitment hospital [15] 0 0
Maroondah Hospital; Breast Clinic - Ringwood East
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2480 - Lismore
Recruitment postcode(s) [3] 0 0
2113 - Macquarie Park
Recruitment postcode(s) [4] 0 0
2076 - Wahroonga
Recruitment postcode(s) [5] 0 0
4066 - Auchenflower
Recruitment postcode(s) [6] 0 0
4032 - Chermside
Recruitment postcode(s) [7] 0 0
4101 - South Brisbane
Recruitment postcode(s) [8] 0 0
4215 - Southport
Recruitment postcode(s) [9] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [10] 0 0
5000 - Adelaide
Recruitment postcode(s) [11] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [12] 0 0
3168 - Clayton
Recruitment postcode(s) [13] 0 0
3084 - Heidelberg
Recruitment postcode(s) [14] 0 0
3135 - Ringwood East
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New Hampshire
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Tennessee
Country [12] 0 0
United States of America
State/province [12] 0 0
Utah
Country [13] 0 0
United States of America
State/province [13] 0 0
West Virginia
Country [14] 0 0
Argentina
State/province [14] 0 0
Berazategui
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudad Autonoma Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Cordoba
Country [17] 0 0
Argentina
State/province [17] 0 0
Jujuy
Country [18] 0 0
Argentina
State/province [18] 0 0
La Rioja
Country [19] 0 0
Argentina
State/province [19] 0 0
Rosario
Country [20] 0 0
Argentina
State/province [20] 0 0
San Miguel de Tucuman
Country [21] 0 0
Argentina
State/province [21] 0 0
Viedma
Country [22] 0 0
Austria
State/province [22] 0 0
Innsbruck
Country [23] 0 0
Austria
State/province [23] 0 0
Linz
Country [24] 0 0
Austria
State/province [24] 0 0
Salzburg
Country [25] 0 0
Austria
State/province [25] 0 0
Vienna
Country [26] 0 0
Austria
State/province [26] 0 0
Vöcklabruck
Country [27] 0 0
Austria
State/province [27] 0 0
Wels
Country [28] 0 0
Austria
State/province [28] 0 0
Wien
Country [29] 0 0
Belgium
State/province [29] 0 0
Brasschaat
Country [30] 0 0
Belgium
State/province [30] 0 0
Bruxelles
Country [31] 0 0
Belgium
State/province [31] 0 0
Leuven
Country [32] 0 0
Belgium
State/province [32] 0 0
Liege
Country [33] 0 0
Belgium
State/province [33] 0 0
Liège
Country [34] 0 0
Belgium
State/province [34] 0 0
Mons
Country [35] 0 0
Belgium
State/province [35] 0 0
Namur
Country [36] 0 0
Belgium
State/province [36] 0 0
Sint Niklaas
Country [37] 0 0
Brazil
State/province [37] 0 0
BA
Country [38] 0 0
Brazil
State/province [38] 0 0
CE
Country [39] 0 0
Brazil
State/province [39] 0 0
RJ
Country [40] 0 0
Brazil
State/province [40] 0 0
RS
Country [41] 0 0
Brazil
State/province [41] 0 0
SC
Country [42] 0 0
Brazil
State/province [42] 0 0
SP
Country [43] 0 0
China
State/province [43] 0 0
Beijing
Country [44] 0 0
China
State/province [44] 0 0
Changchun City
Country [45] 0 0
China
State/province [45] 0 0
Changchun
Country [46] 0 0
China
State/province [46] 0 0
Chengdu
Country [47] 0 0
China
State/province [47] 0 0
Chongqing
Country [48] 0 0
China
State/province [48] 0 0
Fuzhou City
Country [49] 0 0
China
State/province [49] 0 0
Fuzhou
Country [50] 0 0
China
State/province [50] 0 0
Guangzhou
Country [51] 0 0
China
State/province [51] 0 0
Hangzhou
Country [52] 0 0
China
State/province [52] 0 0
Harbin
Country [53] 0 0
China
State/province [53] 0 0
Jinan
Country [54] 0 0
China
State/province [54] 0 0
Luoyang City
Country [55] 0 0
China
State/province [55] 0 0
Nanjing City
Country [56] 0 0
China
State/province [56] 0 0
Shanghai City
Country [57] 0 0
China
State/province [57] 0 0
Shanghai
Country [58] 0 0
China
State/province [58] 0 0
Shenzhen City
Country [59] 0 0
China
State/province [59] 0 0
Shijiazhuang
Country [60] 0 0
China
State/province [60] 0 0
Wuhan City
Country [61] 0 0
China
State/province [61] 0 0
Wuhan
Country [62] 0 0
China
State/province [62] 0 0
Xi'an City
Country [63] 0 0
China
State/province [63] 0 0
Zhejiang
Country [64] 0 0
China
State/province [64] 0 0
Zhengzhou
Country [65] 0 0
Czechia
State/province [65] 0 0
Horovice
Country [66] 0 0
Czechia
State/province [66] 0 0
Praha 2
Country [67] 0 0
Czechia
State/province [67] 0 0
Zlin
Country [68] 0 0
Denmark
State/province [68] 0 0
Herlev
Country [69] 0 0
Denmark
State/province [69] 0 0
Odense C
Country [70] 0 0
Denmark
State/province [70] 0 0
Vejle
Country [71] 0 0
France
State/province [71] 0 0
Ars-Laquenexy
Country [72] 0 0
France
State/province [72] 0 0
Avignon
Country [73] 0 0
France
State/province [73] 0 0
Beauvais
Country [74] 0 0
France
State/province [74] 0 0
Besançon
Country [75] 0 0
France
State/province [75] 0 0
Bordeaux
Country [76] 0 0
France
State/province [76] 0 0
Bourg-en- Bresse Cedex
Country [77] 0 0
France
State/province [77] 0 0
Brest
Country [78] 0 0
France
State/province [78] 0 0
Caen
Country [79] 0 0
France
State/province [79] 0 0
Cholet
Country [80] 0 0
France
State/province [80] 0 0
Compiegne
Country [81] 0 0
France
State/province [81] 0 0
Contamine Sur Arve
Country [82] 0 0
France
State/province [82] 0 0
Dijon
Country [83] 0 0
France
State/province [83] 0 0
La Roche Sur Yon
Country [84] 0 0
France
State/province [84] 0 0
Limoges
Country [85] 0 0
France
State/province [85] 0 0
Lorient
Country [86] 0 0
France
State/province [86] 0 0
Lyon
Country [87] 0 0
France
State/province [87] 0 0
Marseille
Country [88] 0 0
France
State/province [88] 0 0
Montpellier
Country [89] 0 0
France
State/province [89] 0 0
Nantes
Country [90] 0 0
France
State/province [90] 0 0
Nice
Country [91] 0 0
France
State/province [91] 0 0
Pringy
Country [92] 0 0
France
State/province [92] 0 0
Quimper
Country [93] 0 0
France
State/province [93] 0 0
Reims
Country [94] 0 0
France
State/province [94] 0 0
Rouen
Country [95] 0 0
France
State/province [95] 0 0
St Priest en Jarez CEDEX
Country [96] 0 0
France
State/province [96] 0 0
Strasbourg
Country [97] 0 0
France
State/province [97] 0 0
Thonon Les Bains
Country [98] 0 0
France
State/province [98] 0 0
Toulouse
Country [99] 0 0
France
State/province [99] 0 0
Tours
Country [100] 0 0
France
State/province [100] 0 0
Valence
Country [101] 0 0
France
State/province [101] 0 0
Vandoeuvre-Les-Nancy
Country [102] 0 0
France
State/province [102] 0 0
Villejuif
Country [103] 0 0
Germany
State/province [103] 0 0
Berlin
Country [104] 0 0
Germany
State/province [104] 0 0
Dortmund
Country [105] 0 0
Germany
State/province [105] 0 0
Dresden
Country [106] 0 0
Germany
State/province [106] 0 0
Erfurt
Country [107] 0 0
Germany
State/province [107] 0 0
Gütersloh
Country [108] 0 0
Germany
State/province [108] 0 0
Hamburg
Country [109] 0 0
Germany
State/province [109] 0 0
Hildesheim
Country [110] 0 0
Germany
State/province [110] 0 0
Karlsruhe
Country [111] 0 0
Germany
State/province [111] 0 0
Köln
Country [112] 0 0
Germany
State/province [112] 0 0
Ludwigsburg
Country [113] 0 0
Germany
State/province [113] 0 0
Mainz
Country [114] 0 0
Germany
State/province [114] 0 0
Mayen
Country [115] 0 0
Germany
State/province [115] 0 0
Memmingen
Country [116] 0 0
Germany
State/province [116] 0 0
Minden
Country [117] 0 0
Germany
State/province [117] 0 0
Mönchengladbach
Country [118] 0 0
Germany
State/province [118] 0 0
München
Country [119] 0 0
Germany
State/province [119] 0 0
Neumarkt i.d.OPf.
Country [120] 0 0
Germany
State/province [120] 0 0
Offenbach
Country [121] 0 0
Germany
State/province [121] 0 0
Stendal
Country [122] 0 0
Germany
State/province [122] 0 0
Stralsund
Country [123] 0 0
Germany
State/province [123] 0 0
Tübingen
Country [124] 0 0
Germany
State/province [124] 0 0
Weinheim
Country [125] 0 0
Germany
State/province [125] 0 0
Witten
Country [126] 0 0
Germany
State/province [126] 0 0
Worms
Country [127] 0 0
Hong Kong
State/province [127] 0 0
Hong Kong
Country [128] 0 0
Hong Kong
State/province [128] 0 0
Kowloon
Country [129] 0 0
Hungary
State/province [129] 0 0
Budapest
Country [130] 0 0
Hungary
State/province [130] 0 0
Miskolc
Country [131] 0 0
Hungary
State/province [131] 0 0
Pécs
Country [132] 0 0
Ireland
State/province [132] 0 0
Dublin
Country [133] 0 0
Israel
State/province [133] 0 0
Jerusalem
Country [134] 0 0
Israel
State/province [134] 0 0
Kfar Sava
Country [135] 0 0
Israel
State/province [135] 0 0
Petach Tikva
Country [136] 0 0
Israel
State/province [136] 0 0
Ramat Gan
Country [137] 0 0
Italy
State/province [137] 0 0
Abruzzo
Country [138] 0 0
Italy
State/province [138] 0 0
Emilia-Romagna
Country [139] 0 0
Italy
State/province [139] 0 0
Friuli-Venezia Giulia
Country [140] 0 0
Italy
State/province [140] 0 0
Lazio
Country [141] 0 0
Italy
State/province [141] 0 0
Liguria
Country [142] 0 0
Italy
State/province [142] 0 0
Lombardia
Country [143] 0 0
Italy
State/province [143] 0 0
Piemonte
Country [144] 0 0
Italy
State/province [144] 0 0
Toscana
Country [145] 0 0
Italy
State/province [145] 0 0
Umbria
Country [146] 0 0
Japan
State/province [146] 0 0
Aichi
Country [147] 0 0
Japan
State/province [147] 0 0
Chiba
Country [148] 0 0
Japan
State/province [148] 0 0
Ehime
Country [149] 0 0
Japan
State/province [149] 0 0
Fukuoka
Country [150] 0 0
Japan
State/province [150] 0 0
Hiroshima
Country [151] 0 0
Japan
State/province [151] 0 0
Hokkaido
Country [152] 0 0
Japan
State/province [152] 0 0
Hyogo
Country [153] 0 0
Japan
State/province [153] 0 0
Ibaraki
Country [154] 0 0
Japan
State/province [154] 0 0
Kagoshima
Country [155] 0 0
Japan
State/province [155] 0 0
Kanagawa
Country [156] 0 0
Japan
State/province [156] 0 0
Kyoto
Country [157] 0 0
Japan
State/province [157] 0 0
Miyagi
Country [158] 0 0
Japan
State/province [158] 0 0
Okayama
Country [159] 0 0
Japan
State/province [159] 0 0
Okinawa
Country [160] 0 0
Japan
State/province [160] 0 0
Osaka
Country [161] 0 0
Japan
State/province [161] 0 0
Saitama
Country [162] 0 0
Japan
State/province [162] 0 0
Shizuoka
Country [163] 0 0
Japan
State/province [163] 0 0
Tokyo
Country [164] 0 0
Korea, Republic of
State/province [164] 0 0
Cheongju si
Country [165] 0 0
Korea, Republic of
State/province [165] 0 0
Dongnam-gu, Cheonan-si
Country [166] 0 0
Korea, Republic of
State/province [166] 0 0
Goyang-si
Country [167] 0 0
Korea, Republic of
State/province [167] 0 0
Gyeonggi-do
Country [168] 0 0
Korea, Republic of
State/province [168] 0 0
Incheon
Country [169] 0 0
Korea, Republic of
State/province [169] 0 0
Seongnam-si
Country [170] 0 0
Korea, Republic of
State/province [170] 0 0
Seoul
Country [171] 0 0
Korea, Republic of
State/province [171] 0 0
Suwon City
Country [172] 0 0
Korea, Republic of
State/province [172] 0 0
Ulsan
Country [173] 0 0
Korea, Republic of
State/province [173] 0 0
Wonju
Country [174] 0 0
Mexico
State/province [174] 0 0
Mexico CITY (federal District)
Country [175] 0 0
Mexico
State/province [175] 0 0
Nuevo LEON
Country [176] 0 0
Mexico
State/province [176] 0 0
Oaxaca
Country [177] 0 0
Mexico
State/province [177] 0 0
SAN LUIS Potosi
Country [178] 0 0
Mexico
State/province [178] 0 0
Yucatan
Country [179] 0 0
Mexico
State/province [179] 0 0
Mexico City
Country [180] 0 0
Peru
State/province [180] 0 0
Arequipa
Country [181] 0 0
Peru
State/province [181] 0 0
Lima
Country [182] 0 0
Poland
State/province [182] 0 0
?ód?
Country [183] 0 0
Poland
State/province [183] 0 0
Poznan
Country [184] 0 0
Poland
State/province [184] 0 0
Warszawa
Country [185] 0 0
Romania
State/province [185] 0 0
Bucharest
Country [186] 0 0
Romania
State/province [186] 0 0
Cluj Napoca
Country [187] 0 0
Romania
State/province [187] 0 0
Craiova
Country [188] 0 0
Russian Federation
State/province [188] 0 0
Adygeja
Country [189] 0 0
Russian Federation
State/province [189] 0 0
Arhangelsk
Country [190] 0 0
Russian Federation
State/province [190] 0 0
Baskortostan
Country [191] 0 0
Russian Federation
State/province [191] 0 0
Jaroslavl
Country [192] 0 0
Russian Federation
State/province [192] 0 0
Krasnodar
Country [193] 0 0
Russian Federation
State/province [193] 0 0
Kurgan
Country [194] 0 0
Russian Federation
State/province [194] 0 0
Mordovija
Country [195] 0 0
Russian Federation
State/province [195] 0 0
Moskovskaja Oblast
Country [196] 0 0
Russian Federation
State/province [196] 0 0
Niznij Novgorod
Country [197] 0 0
Russian Federation
State/province [197] 0 0
Rostov
Country [198] 0 0
Russian Federation
State/province [198] 0 0
Sankt Petersburg
Country [199] 0 0
Russian Federation
State/province [199] 0 0
Stavropol
Country [200] 0 0
Russian Federation
State/province [200] 0 0
Irkutsk
Country [201] 0 0
Russian Federation
State/province [201] 0 0
Ivanovo
Country [202] 0 0
Russian Federation
State/province [202] 0 0
Novgorod Veliky
Country [203] 0 0
Russian Federation
State/province [203] 0 0
Omsk
Country [204] 0 0
Russian Federation
State/province [204] 0 0
Samara
Country [205] 0 0
Russian Federation
State/province [205] 0 0
Saratov
Country [206] 0 0
Russian Federation
State/province [206] 0 0
Volgograd
Country [207] 0 0
Singapore
State/province [207] 0 0
Singapore
Country [208] 0 0
Spain
State/province [208] 0 0
Barcelona
Country [209] 0 0
Spain
State/province [209] 0 0
Cadiz
Country [210] 0 0
Spain
State/province [210] 0 0
Castellon
Country [211] 0 0
Spain
State/province [211] 0 0
Islas Baleares
Country [212] 0 0
Spain
State/province [212] 0 0
LA Coruña
Country [213] 0 0
Spain
State/province [213] 0 0
Madrid
Country [214] 0 0
Spain
State/province [214] 0 0
Pontevedra
Country [215] 0 0
Spain
State/province [215] 0 0
Tarragona
Country [216] 0 0
Spain
State/province [216] 0 0
Tenerife
Country [217] 0 0
Spain
State/province [217] 0 0
Burgos
Country [218] 0 0
Spain
State/province [218] 0 0
Caceres
Country [219] 0 0
Spain
State/province [219] 0 0
Jaen
Country [220] 0 0
Spain
State/province [220] 0 0
Leon
Country [221] 0 0
Spain
State/province [221] 0 0
Malaga
Country [222] 0 0
Spain
State/province [222] 0 0
Murcia
Country [223] 0 0
Spain
State/province [223] 0 0
Sevilla
Country [224] 0 0
Spain
State/province [224] 0 0
Valencia
Country [225] 0 0
Spain
State/province [225] 0 0
Zaragoza
Country [226] 0 0
Switzerland
State/province [226] 0 0
Aarau
Country [227] 0 0
Switzerland
State/province [227] 0 0
Lausanne
Country [228] 0 0
Switzerland
State/province [228] 0 0
Zürich
Country [229] 0 0
Taiwan
State/province [229] 0 0
Changhua
Country [230] 0 0
Taiwan
State/province [230] 0 0
Kaoshiung City
Country [231] 0 0
Taiwan
State/province [231] 0 0
Kaoshiung
Country [232] 0 0
Taiwan
State/province [232] 0 0
Liuying Township
Country [233] 0 0
Taiwan
State/province [233] 0 0
Tainan
Country [234] 0 0
Taiwan
State/province [234] 0 0
Taipei City
Country [235] 0 0
Taiwan
State/province [235] 0 0
Taipei
Country [236] 0 0
Taiwan
State/province [236] 0 0
Taoyuan City
Country [237] 0 0
Thailand
State/province [237] 0 0
Bangkok
Country [238] 0 0
Thailand
State/province [238] 0 0
Hat Yai
Country [239] 0 0
Thailand
State/province [239] 0 0
Khon Kaen
Country [240] 0 0
Thailand
State/province [240] 0 0
Muang Lampang
Country [241] 0 0
Thailand
State/province [241] 0 0
Patumwan
Country [242] 0 0
Turkey
State/province [242] 0 0
Adana
Country [243] 0 0
Turkey
State/province [243] 0 0
Bursa
Country [244] 0 0
Turkey
State/province [244] 0 0
Izmir
Country [245] 0 0
Turkey
State/province [245] 0 0
Mersin
Country [246] 0 0
Turkey
State/province [246] 0 0
Samsun
Country [247] 0 0
Ukraine
State/province [247] 0 0
Katerynoslav Governorate
Country [248] 0 0
Ukraine
State/province [248] 0 0
KIEV Governorate
Country [249] 0 0
Ukraine
State/province [249] 0 0
Podolia Governorate
Country [250] 0 0
Ukraine
State/province [250] 0 0
Chernigiv
Country [251] 0 0
Ukraine
State/province [251] 0 0
Chernivtsi
Country [252] 0 0
Ukraine
State/province [252] 0 0
Dnipropetrovsk
Country [253] 0 0
Ukraine
State/province [253] 0 0
Kirovograd
Country [254] 0 0
Ukraine
State/province [254] 0 0
Kryvyi Rih
Country [255] 0 0
Ukraine
State/province [255] 0 0
Lutsk
Country [256] 0 0
Ukraine
State/province [256] 0 0
Lviv
Country [257] 0 0
Ukraine
State/province [257] 0 0
Odesa
Country [258] 0 0
Ukraine
State/province [258] 0 0
Sumy
Country [259] 0 0
Ukraine
State/province [259] 0 0
Uzhgorod
Country [260] 0 0
Ukraine
State/province [260] 0 0
Zaporizhzhya
Country [261] 0 0
United Kingdom
State/province [261] 0 0
Edinburgh
Country [262] 0 0
United Kingdom
State/province [262] 0 0
Huddersfield
Country [263] 0 0
United Kingdom
State/province [263] 0 0
Leeds
Country [264] 0 0
United Kingdom
State/province [264] 0 0
Manchester
Country [265] 0 0
United Kingdom
State/province [265] 0 0
Nottingham
Country [266] 0 0
United Kingdom
State/province [266] 0 0
Stoke-On-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Breast International Group
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Alliance Foundation Trials (AFT)
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Commercial sector/industry
Name [4] 0 0
Frontier Science & Technology Research Foundation, Inc.
Address [4] 0 0
Country [4] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
Trial website
https://clinicaltrials.gov/study/NCT03498716
Trial related presentations / publications
Perez-Garcia J, Soberino J, Racca F, Gion M, Stradella A, Cortes J. Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03498716